{"protocolSection": {"identificationModule": {"nctId": "NCT02892019", "orgStudyIdInfo": {"id": "CQMF149G2202"}, "secondaryIdInfos": [{"id": "2016-002113-21", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma", "officialTitle": "A Multicenter, Randomized, Double-blind, Active-controlled, 2 Week Treatment, Parallel-group Study to Assess the Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma"}, "statusModule": {"statusVerifiedDate": "2020-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-04-18", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-06-19", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-07-17", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-09-01", "studyFirstSubmitQcDate": "2016-09-01", "studyFirstPostDateStruct": {"date": "2016-09-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-01-15", "resultsFirstSubmitQcDate": "2020-01-15", "resultsFirstPostDateStruct": {"date": "2020-01-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-01-15", "lastUpdatePostDateStruct": {"date": "2020-01-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study is designed to explore lung function effects of two doses of indacaterol acetate, 75 \u03bcg and 150 \u03bcg, in pediatric asthma patients 6-11 years old, and to compare the systemic exposure to indacaterol in plasma with historical data in adults, to identify an appropriate dose to Phase III evaluation."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["indacaterol acetate, asthma, GINA 2015, pediatrics"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 79, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Indacaterol acetate 75 \u03bcg o.d.", "type": "ACTIVE_COMPARATOR", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler", "interventionNames": ["Drug: Indacaterol acetate 75 \u03bcg"]}, {"label": "Indacaterol acetate 150 \u03bcg o.d.", "type": "ACTIVE_COMPARATOR", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler", "interventionNames": ["Drug: Indacaterol acetate 150 \u03bcg"]}], "interventions": [{"type": "DRUG", "name": "Indacaterol acetate 75 \u03bcg", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler", "armGroupLabels": ["Indacaterol acetate 75 \u03bcg o.d."], "otherNames": ["QAB149"]}, {"type": "DRUG", "name": "Indacaterol acetate 150 \u03bcg", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler", "armGroupLabels": ["Indacaterol acetate 150 \u03bcg o.d."], "otherNames": ["QAB149"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Trough Forced Expiratoty Volume in 1 Second (FEV1)", "description": "Change from baseline in pre-dose trough FEV1 after 2 weeks of treatment with indacaterol acetate 75 \u03bcg o.d and 150 \u03bcg o.d.\n\nThe primary endpoint is change from baseline in pre-dose trough FEV1 (mL) after 2 weeks of treatment. The pre-dose trough FEV1 (mL) is defined as the mean of the two FEV1 (mL), values measured at -45 min and -15 min pre-dose.", "timeFrame": "2 weeks"}], "secondaryOutcomes": [{"measure": "Systemic Exposure to Indacaterol in Plasma", "description": "Systemic exposure to indacaterol in plasma following sparse pharmacokinetic (PK) sampling on Day 1 and Day 14 after inhalation of indacaterol acetate 75 \u03bcg and 150 \u03bcg.", "timeFrame": "day 1, day 14"}, {"measure": "Asthma Control as Assessed by Pediatric Interviewer-administered Asthma Control Questionnaire", "description": "Asthma Control as assessed by pediatric interviewer-administered Asthma Control Questionnaire (ACQ-IA) score at week 2 (mean change). A decrease in the score shows an improvement.\n\nThe scale ranges from 0 (no symptoms) to 6 (severe symptoms every day). Results are given as a change as compared from baseline", "timeFrame": "2 weeks"}, {"measure": "Pre-dose Morning and Evening Peak Expiratoty Flow (PEF)", "description": "Pre-dose morning and evening PEF over 2 weeks of treatment as determined by electronic peak flow meter data (mean change)", "timeFrame": "2 weeks"}, {"measure": "Rescue Medication Usage (Mean Daiily Number of Puffs)", "description": "Rescue medication usage over 2 weeks of treatment as determined by patient diary data for indacaterol acetate 75 \u03bcg and 150 \u03bcg o.d.Results given as mean change of puffs of rescue medication.", "timeFrame": "2 weeks"}, {"measure": "Rescue Medication Usage (Percentage of Rescue Medication Free Days)", "description": "Rescue medication usage over 2 weeks of treatment as determined by patient diary data for indacaterol acetate 75 \u03bcg and 150 \u03bcg o.d.", "timeFrame": "2 weeks"}, {"measure": "Forced Expiratoty Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC)", "description": "FEV1 and FVC at 30 minutes and 1-hour post dose at week 2 for indacaterol acetate 75 \u03bcg and 150 \u03bcg o.d.", "timeFrame": "2 weeks"}, {"measure": "Symptoms as Recorded by Patient E-diary (Mean Total Daily Symptom Score)", "description": "Symptoms as recorded by patient e-diary for indacaterol acetate 75 \u03bcg and 150 \u03bcg o.d. (mean change) The scale rages from 0 (no problem) - 4 (very severe problems).", "timeFrame": "2 weeks"}, {"measure": "Symptoms as Recorded by Patient E-diary (Percentage of Asthma Symptoms Free Days)", "description": "Symptoms as recorded by patient e-diary for indacaterol acetate 75 \u03bcg and 150 \u03bcg o.d. (mean change)", "timeFrame": "2 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female children \u2265 6 years and \\< 12 years with confirmed diagnosis of asthma for at least 1 year prior to study enrollment.\n* Written informed consent by parent(s)/legal guardian(s) and depending upon their age and local requirements a consent or assent for the patient.\n* Patients receiving daily treatment with a stable low dose Inhaled Corticosteroid (ICS) (with or without additional controller), or patients receiving daily treatment with a stable mid-dose ICS (monotherapy or together with LTRA) for at least 4 weeks prior to Screening, and able to tolerate fluticasone propionate 100 \u03bcg b.i.d. inhaler starting at Visit 1 (or soon after).\n* Patients with a pre-bronchodilator FEV1 \u2265 50% and \u2264 90% of the predicted normal value for the patient at the start and end of Run-in (Visits 101 and 199).\n* Patients who demonstrate an increase in FEV1 of 12% within 30 minutes after administration of 400 \u03bcg salbutamol/360 \u03bcg albuterol (or equivalent dose) at Visit 101. All patients must perform a reversibility test at Visit 101.\n\nExclusion Criteria:\n\n* Patients taking a mid-dose ICS (per GINA guidelines) in combination with LABA or any patient taking high-dose ICS.\n* Evidence of unstable disease within 4 weeks prior to Screening (Visit 1).\n* Patients who have had an asthma attack/exacerbation requiring systemic steroids (SCS) or hospitalization or emergency room visit within 3 months prior to Visit 1 (Screening) or more than 3 separate exacerbations in the 12 months preceding Visit 1.\n* Suspected or documented bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Screening (Visit 1).\n* Prior intubation for asthma.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Brugge", "zip": "8000", "country": "Belgium", "geoPoint": {"lat": 51.20892, "lon": 3.22424}}, {"facility": "Novartis Investigative Site", "city": "Brussel", "zip": "1020", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Novartis Investigative Site", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Novartis Investigative Site", "city": "Bucaramanga", "country": "Colombia", "geoPoint": {"lat": 7.12539, "lon": -73.1198}}, {"facility": "Novartis Investigative Site", "city": "Slavonski Brod", "zip": "35000", "country": "Croatia", "geoPoint": {"lat": 45.16028, "lon": 18.01556}}, {"facility": "Novartis Investigative Site", "city": "Zagreb", "zip": "10000", "country": "Croatia", "geoPoint": {"lat": 45.81444, "lon": 15.97798}}, {"facility": "Novartis Investigative Site", "city": "Hamm", "zip": "D 59063", "country": "Germany", "geoPoint": {"lat": 51.68033, "lon": 7.82089}}, {"facility": "Novartis Investigative Site", "city": "Mannheim", "zip": "68161", "country": "Germany", "geoPoint": {"lat": 49.4891, "lon": 8.46694}}, {"facility": "Novartis Investigative Site", "city": "Rosenheim", "zip": "83026", "country": "Germany", "geoPoint": {"lat": 47.85637, "lon": 12.12247}}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "state": "GTM", "zip": "01010", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "zip": "01011", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "zip": "01015", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Torokbalint", "state": "Pest", "zip": "2045", "country": "Hungary", "geoPoint": {"lat": 47.42931, "lon": 18.91356}}, {"facility": "Novartis Investigative Site", "city": "Budapest", "zip": "1083", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novartis Investigative Site", "city": "Szeged", "zip": "6720", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Novartis Investigative Site", "city": "Szigetvar", "zip": "7900", "country": "Hungary", "geoPoint": {"lat": 46.04865, "lon": 17.80554}}, {"facility": "Novartis Investigative Site", "city": "Manila", "state": "Metro Manila", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Novartis Investigative Site", "city": "Manila", "zip": "1008", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Novartis Investigative Site", "city": "Quezon City", "zip": "1113", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Novartis Investigative Site", "city": "Saint Petersburg", "zip": "199106", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "St.Petersburg", "zip": "196240", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Nitra", "state": "Slovak Republic", "zip": "949 01", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"facility": "Novartis Investigative Site", "city": "Nove Zamky", "state": "SVK", "zip": "94001", "country": "Slovakia", "geoPoint": {"lat": 47.98544, "lon": 18.16195}}, {"facility": "Novartis Investigative Site", "city": "Middelburg", "state": "Mpumalanga", "zip": "1050", "country": "South Africa", "geoPoint": {"lat": -25.77507, "lon": 29.46482}}, {"facility": "Novartis Investigative Site", "city": "Panorama", "state": "Western Cape", "zip": "7500", "country": "South Africa", "geoPoint": {"lat": -25.61314, "lon": 30.52899}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7531", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Adana", "zip": "01330", "country": "Turkey", "geoPoint": {"lat": 37.00167, "lon": 35.32889}}, {"facility": "Novartis Investigative Site", "city": "Ankara", "zip": "06100", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED", "description": "Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "randomized set : 80 participants (41 and 39) Full analysis set : 79 participants (41 and 38) safety set : 79 participants (41 and 38) per protocol set : 35 participants (35 and 34)", "groups": [{"id": "FG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "FG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "39"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "36"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "randomized but not treated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "BG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "80"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.3", "spread": "1.47"}, {"groupId": "BG001", "value": "9.1", "spread": "1.58"}, {"groupId": "BG002", "value": "9.2", "spread": "1.51"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "28"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "52"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "34"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}]}, {"title": "Native American", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "29"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Trough Forced Expiratoty Volume in 1 Second (FEV1)", "description": "Change from baseline in pre-dose trough FEV1 after 2 weeks of treatment with indacaterol acetate 75 \u03bcg o.d and 150 \u03bcg o.d.\n\nThe primary endpoint is change from baseline in pre-dose trough FEV1 (mL) after 2 weeks of treatment. The pre-dose trough FEV1 (mL) is defined as the mean of the two FEV1 (mL), values measured at -45 min and -15 min pre-dose.", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "OG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "38"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.171", "spread": "0.1664"}, {"groupId": "OG001", "value": "0.212", "spread": "0.2521"}]}]}]}, {"type": "SECONDARY", "title": "Systemic Exposure to Indacaterol in Plasma", "description": "Systemic exposure to indacaterol in plasma following sparse pharmacokinetic (PK) sampling on Day 1 and Day 14 after inhalation of indacaterol acetate 75 \u03bcg and 150 \u03bcg.", "populationDescription": "safety set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "day 1, day 14", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "OG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "38"}]}], "classes": [{"title": "Day 1 <=-2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "0.0"}, {"groupId": "OG001", "value": "0.0", "spread": "0.0"}]}]}, {"title": "Day 1, 15 minutes", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "34"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "204.1", "spread": "98.27"}, {"groupId": "OG001", "value": "73.7", "spread": "39.55"}]}]}, {"title": "Day 1, 1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "32"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "125.8", "spread": "63.13"}, {"groupId": "OG001", "value": "43.9", "spread": "20.84"}]}]}, {"title": "Day 14 <=-2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "31"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "80.9", "spread": "32.51"}, {"groupId": "OG001", "value": "46.7", "spread": "29.61"}]}]}, {"title": "Day 14, 15 minutes", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "393.1", "spread": "182.11"}, {"groupId": "OG001", "value": "137.3", "spread": "47.43"}]}]}, {"title": "Day 14, 1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "34"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "255.5", "spread": "117.67"}, {"groupId": "OG001", "value": "103.0", "spread": "37.88"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Control as Assessed by Pediatric Interviewer-administered Asthma Control Questionnaire", "description": "Asthma Control as assessed by pediatric interviewer-administered Asthma Control Questionnaire (ACQ-IA) score at week 2 (mean change). A decrease in the score shows an improvement.\n\nThe scale ranges from 0 (no symptoms) to 6 (severe symptoms every day). Results are given as a change as compared from baseline", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "OG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "38"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.375", "spread": "0.3796"}, {"groupId": "OG001", "value": "-0.270", "spread": "0.6341"}]}]}]}, {"type": "SECONDARY", "title": "Pre-dose Morning and Evening Peak Expiratoty Flow (PEF)", "description": "Pre-dose morning and evening PEF over 2 weeks of treatment as determined by electronic peak flow meter data (mean change)", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "OG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "38"}]}], "classes": [{"title": "Morning PEF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "37"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29.6", "spread": "26.41"}, {"groupId": "OG001", "value": "14.7", "spread": "29.38"}]}]}, {"title": "Evening PEF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "37"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29.7", "spread": "25.57"}, {"groupId": "OG001", "value": "15.2", "spread": "28.58"}]}]}]}, {"type": "SECONDARY", "title": "Rescue Medication Usage (Mean Daiily Number of Puffs)", "description": "Rescue medication usage over 2 weeks of treatment as determined by patient diary data for indacaterol acetate 75 \u03bcg and 150 \u03bcg o.d.Results given as mean change of puffs of rescue medication.", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "number of puffs", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "OG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "38"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.19", "spread": "1.479"}, {"groupId": "OG001", "value": "-0.22", "spread": "0.930"}]}]}]}, {"type": "SECONDARY", "title": "Rescue Medication Usage (Percentage of Rescue Medication Free Days)", "description": "Rescue medication usage over 2 weeks of treatment as determined by patient diary data for indacaterol acetate 75 \u03bcg and 150 \u03bcg o.d.", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "OG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "38"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.4", "spread": "22.37"}, {"groupId": "OG001", "value": "3.1", "spread": "19.42"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratoty Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC)", "description": "FEV1 and FVC at 30 minutes and 1-hour post dose at week 2 for indacaterol acetate 75 \u03bcg and 150 \u03bcg o.d.", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "OG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "38"}]}], "classes": [{"title": "30 minutes", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "34"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.234", "spread": "0.1786"}, {"groupId": "OG001", "value": "0.224", "spread": "0.2459"}]}]}, {"title": "1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.224", "spread": "0.1725"}, {"groupId": "OG001", "value": "0.258", "spread": "0.2451"}]}]}]}, {"type": "SECONDARY", "title": "Symptoms as Recorded by Patient E-diary (Mean Total Daily Symptom Score)", "description": "Symptoms as recorded by patient e-diary for indacaterol acetate 75 \u03bcg and 150 \u03bcg o.d. (mean change) The scale rages from 0 (no problem) - 4 (very severe problems).", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "OG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "38"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.18", "spread": "0.695"}, {"groupId": "OG001", "value": "0.08", "spread": "0.365"}]}]}]}, {"type": "SECONDARY", "title": "Symptoms as Recorded by Patient E-diary (Percentage of Asthma Symptoms Free Days)", "description": "Symptoms as recorded by patient e-diary for indacaterol acetate 75 \u03bcg and 150 \u03bcg o.d. (mean change)", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 150 \u03bcg o.d.", "description": "Indacaterol acetate 150 \u03bcg o.d. delivered via Concept1 inhaler"}, {"id": "OG001", "title": "Indacaterol Acetate 75 \u03bcg o.d.", "description": "Indacaterol acetate 75 \u03bcg o.d. delivered via Concept1 inhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "38"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.3", "spread": "21.25"}, {"groupId": "OG001", "value": "4.4", "spread": "26.60"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "2 years", "description": "AE additional description", "eventGroups": [{"id": "EG000", "title": "QAB149 150 ug OD", "description": "QAB149 150 ug OD", "deathsNumAffected": 0, "deathsNumAtRisk": 41, "seriousNumAffected": 0, "seriousNumAtRisk": 41, "otherNumAffected": 3, "otherNumAtRisk": 41}, {"id": "EG001", "title": "QAB149 75 ug OD", "description": "QAB149 75 ug OD", "deathsNumAffected": 0, "deathsNumAtRisk": 38, "seriousNumAffected": 0, "seriousNumAtRisk": 38, "otherNumAffected": 13, "otherNumAtRisk": 38}], "otherEvents": [{"term": "Defect conduction intraventricular", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 38}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 38}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 38}]}, {"term": "Conjunctivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 38}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 38}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 38}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 38}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 38}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 38}]}, {"term": "Peak expiratory flow rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 38}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 38}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 38}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 38}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "novartis.email@novartis.com", "phone": "862-778-8300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-08-27", "uploadDate": "2020-01-15T08:48", "filename": "SAP_000.pdf", "size": 552148}, {"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2016-06-28", "uploadDate": "2020-01-15T08:48", "filename": "Prot_001.pdf", "size": 1772584}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}